Keywords: |
treatment planning; conference paper; cancer radiotherapy; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; cancer diagnosis; radiopharmaceuticals; neoplasms; animals; computer assisted tomography; neoplasm proteins; tumor markers, biological; tomography, x-ray computed; tumor biopsy; neovascularization, pathologic; hypoxia; imaging system; device; fluorodeoxyglucose f18; research; radiosensitivity; cell hypoxia; misonidazole; radiotherapy planning, computer-assisted; tracer; radioisotope; molecular biology; single photon emission computer tomography; radiodiagnosis; fluorodeoxyglucose; thymidine; tomography, emission-computed; receptors, cell surface; tomography, emission-computed, single-photon; radiation tolerance; 2 nitroimidazole; tomography scanners, x-ray computed; nucleoside derivative; cancer; humans; human; priority journal; bms 194796; oxo[3,3,9,9 tetramethyl 1 (2 nitro 1h imidazol 1 yl) 4,8 diazaundecane 2,10 dionedioximato]technetium tc 99m
|